DE60314017D1 - Chimaeres protein enthaltend die cystein protease aus dem grossen leberegel fusioniert an das hepatitis b core protein oder ubiquitin; pflanzen, welches dieses protein exprimieren, sowie deren verwendung als vakzine - Google Patents

Chimaeres protein enthaltend die cystein protease aus dem grossen leberegel fusioniert an das hepatitis b core protein oder ubiquitin; pflanzen, welches dieses protein exprimieren, sowie deren verwendung als vakzine

Info

Publication number
DE60314017D1
DE60314017D1 DE60314017T DE60314017T DE60314017D1 DE 60314017 D1 DE60314017 D1 DE 60314017D1 DE 60314017 T DE60314017 T DE 60314017T DE 60314017 T DE60314017 T DE 60314017T DE 60314017 D1 DE60314017 D1 DE 60314017D1
Authority
DE
Germany
Prior art keywords
protein
livergel
fusioned
ubiquitin
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60314017T
Other languages
English (en)
Other versions
DE60314017T2 (de
Inventor
Andrzej B Legocki
Katarzyna Miedzinska
Magdalena Czaplinska
Anna Modelska
Tomasz Pniewski
Andrzej Plucienniczak
Malgorzata Kezik
Anna Porebska
Halina Wedrychowicz
Juliusz Mieszczanek
Luiza Jedlina-Panasiuk
Jacek Wojciechowicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INST OF BIOORG CHEMISTRY
INST OF BIOTECHNOLOGY ANTIBIOT
Institute of Biotechnology and Antibiotics
Original Assignee
INST OF BIOORG CHEMISTRY
INST OF BIOTECHNOLOGY ANTIBIOT
Institute of Biotechnology and Antibiotics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INST OF BIOORG CHEMISTRY, INST OF BIOTECHNOLOGY ANTIBIOT, Institute of Biotechnology and Antibiotics filed Critical INST OF BIOORG CHEMISTRY
Publication of DE60314017D1 publication Critical patent/DE60314017D1/de
Application granted granted Critical
Publication of DE60314017T2 publication Critical patent/DE60314017T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/641—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60314017T 2002-12-04 2003-12-04 Chimaeres protein enthaltend die cystein protease aus dem grossen leberegel fusioniert an das hepatitis b core protein oder ubiquitin; pflanzen, welches dieses protein exprimieren, sowie deren verwendung als vakzine Expired - Fee Related DE60314017T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL35751702 2002-12-04
PL357517A PL201419B1 (pl) 2002-12-04 2002-12-04 Białko chimeryczne, sekwencja, konstrukt, komórka roślinna, sposób otrzymywania białka chimerycznego, transgenicznej rośliny, transgeniczna roślina
PCT/PL2003/000135 WO2004050883A2 (en) 2002-12-04 2003-12-04 Chimaeric protein containing cysteine protease of liver fluke fused to hepatitis b core protein or ubiquitin, plants expressing said protein, and uses thereof as vaccine

Publications (2)

Publication Number Publication Date
DE60314017D1 true DE60314017D1 (de) 2007-07-05
DE60314017T2 DE60314017T2 (de) 2008-01-17

Family

ID=32464755

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60314017T Expired - Fee Related DE60314017T2 (de) 2002-12-04 2003-12-04 Chimaeres protein enthaltend die cystein protease aus dem grossen leberegel fusioniert an das hepatitis b core protein oder ubiquitin; pflanzen, welches dieses protein exprimieren, sowie deren verwendung als vakzine

Country Status (9)

Country Link
EP (1) EP1613752B1 (de)
AT (1) ATE362988T1 (de)
AU (1) AU2003295293B2 (de)
DE (1) DE60314017T2 (de)
DK (1) DK1613752T3 (de)
ES (1) ES2288223T3 (de)
NZ (1) NZ540582A (de)
PL (1) PL201419B1 (de)
WO (1) WO2004050883A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL196114B1 (pl) * 2002-12-31 2007-12-31 Inst Biotechnologii I Antybiot Ciałka inkluzyjne jako antygeny do doustnej immunizacji zwierząt
CA2570566A1 (en) * 2004-06-25 2006-01-12 Altor Bioscience Corporation Production of tissue factor in plants
US9610335B2 (en) * 2009-12-10 2017-04-04 Escola Superior Agrária De Coimbra Immunogens, compositions and uses thereof, method for preparing same
WO2014124047A1 (en) * 2013-02-06 2014-08-14 Academia Sinica Antimicrobial peptides derived from hepatitis b virus core protein arginine-rich domain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3048689A (en) * 1988-01-13 1989-08-11 University Of North Carolina At Chapel Hill, The Immunogenic peptides
EP0666919B1 (de) * 1992-10-21 2003-05-14 John Pius Dalton Thiolprotease enthaltender impfstoff
EP0647138A4 (de) * 1993-02-05 1996-03-06 Daratech Pty Ltd Polypeptide erhältlich aus fasciola spezien, und vakzine, therapieverfahren und dna sequenzen diese peptide kodierend.
GB9312324D0 (en) * 1993-06-15 1993-07-28 Pitman Moore Inc Vaccine
US6319503B1 (en) * 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system

Also Published As

Publication number Publication date
EP1613752B1 (de) 2007-05-23
WO2004050883A3 (en) 2004-11-04
PL357517A1 (en) 2004-06-14
AU2003295293B2 (en) 2009-12-03
AU2003295293A1 (en) 2004-06-23
ES2288223T3 (es) 2008-01-01
DE60314017T2 (de) 2008-01-17
WO2004050883A2 (en) 2004-06-17
DK1613752T3 (da) 2007-09-10
ATE362988T1 (de) 2007-06-15
EP1613752A2 (de) 2006-01-11
NZ540582A (en) 2008-05-30
PL201419B1 (pl) 2009-04-30

Similar Documents

Publication Publication Date Title
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
WO2001077311A3 (en) Transcription factor stress-related proteins and methods of use in plants
CL2011001769A1 (es) Composición para estimular una respuesta inmune contra la toxina shiga stx2 que comprende polipéptidos que comprenden al menos dos de las tres regiones que definen un epitopo conformacional exclusivo de stx2, los cuales se insertan dentro de una proteína andamio no stx2; dicho polipéptido; ácido nucleico; y método de producción de anticuerpos.
HUP0303050A2 (hu) Növényi transzkripciós faktorok
ME00314B (me) Anti-tnf antitijela, kompozicije, postupci i primjene
HRP20030088A2 (en) Anti-dual integrin antibodies, compositions, methods and uses
HUP0002475A2 (hu) Módosított immunogén pneumolizinkészítmények mint vakcinák
HRP20130028T1 (hr) Rekombinantna ko-ekspresija podjedinice reduktaze vitamin k epoksida u svrhu poboljšanja ekspresije vitamin k-ovisnog proteina
HUP0303843A2 (hu) CLyA-hemolizin alkalmazása proteinek exkretáltatására
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
NO20053328D0 (no) Immunisering av fisk med uttrykte proteiner i planteceller.
AR015255A1 (es) Un fragmento de adn que conduce naturalmente la expresion de un gen vegetal que codifica para hexosa oxidasa o una porcion o una variante del fragmento deadn; una secuencia de adn quimerico que comprende el fragmento de adn; celulas vegetales, plantas y partes de plantas que comprenden la secuencia
DE60314017D1 (de) Chimaeres protein enthaltend die cystein protease aus dem grossen leberegel fusioniert an das hepatitis b core protein oder ubiquitin; pflanzen, welches dieses protein exprimieren, sowie deren verwendung als vakzine
DE60110047D1 (de) Zahn-vorläuferzelle und methode für deren herstellung
BR0215665B1 (pt) Proteína da endotoxina delta quimérica cry1ea e cry1ca
DK1303593T3 (da) Anvendelse af CYP52A2A promotor til forögelse af genekspression i gær
AR011740A1 (es) Proteinas del virus que produce enrollamiento en las hojas de la vid del tipo 2, secuencias de codificacion y metodos
MX2007004624A (es) Polipeptidos de transito vesicular relacionados con estres y metodos de uso en plantas.
CY1107784T1 (el) Πρωτεϊνη συντηξης g του ihnv για διεγερση του ανοσοποιητικου συστηματος
WO2004050692A3 (en) Fusion of the e2 protein of csfv with kdel , vts and/or ubiquitin for expression in transgenic plants for vaccine production
EP1916298A4 (de) Antikörperherstellungsverfahren
PL358081A1 (en) Inclusion bodies as antigenes in oral immunization of animals
DE60218463D1 (de) Untereiheitsimpfstoffe und verfahren zur deren herstellung
BR112021017602A2 (pt) Vetores de t-dna com sequências 5' engenheiradas a montante de enzimas de modificação pós-tradução e métodos de uso das mesmas
ATE292184T1 (de) Expression von multiplen proteinen in transgenen pflanzen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee